Benefit–risk of voxelotor, crizanlizumab, and l-glutamine in sickle cell disease: A systematic review

The American Journal of the Medical Sciences · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles